KR102666638B1 - Anti-oxidant, anti-inflammatory and/or immunity enhancing compositioin derived from aruncus dioicus-soybean curd residue containing caffeic acid and vinylcatechol - Google Patents
Anti-oxidant, anti-inflammatory and/or immunity enhancing compositioin derived from aruncus dioicus-soybean curd residue containing caffeic acid and vinylcatechol Download PDFInfo
- Publication number
- KR102666638B1 KR102666638B1 KR1020210056543A KR20210056543A KR102666638B1 KR 102666638 B1 KR102666638 B1 KR 102666638B1 KR 1020210056543 A KR1020210056543 A KR 1020210056543A KR 20210056543 A KR20210056543 A KR 20210056543A KR 102666638 B1 KR102666638 B1 KR 102666638B1
- Authority
- KR
- South Korea
- Prior art keywords
- soybean curd
- snow
- nungaeseungma
- processed product
- heat
- Prior art date
Links
- FBTSUTGMWBDAAC-UHFFFAOYSA-N 3,4-Dihydroxystyrene Chemical compound OC1=CC=C(C=C)C=C1O FBTSUTGMWBDAAC-UHFFFAOYSA-N 0.000 title claims abstract description 19
- 230000003078 antioxidant effect Effects 0.000 title abstract description 39
- 239000003963 antioxidant agent Substances 0.000 title abstract description 31
- 230000003110 anti-inflammatory effect Effects 0.000 title abstract description 17
- 235000006708 antioxidants Nutrition 0.000 title description 29
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 title description 21
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 title description 10
- 229940074360 caffeic acid Drugs 0.000 title description 10
- 235000004883 caffeic acid Nutrition 0.000 title description 10
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 title description 10
- 230000002708 enhancing effect Effects 0.000 title description 5
- 230000036039 immunity Effects 0.000 title description 4
- 241001092053 Aruncus Species 0.000 title description 2
- 235000013527 bean curd Nutrition 0.000 claims abstract description 94
- 239000002131 composite material Substances 0.000 claims abstract description 51
- 240000006677 Vicia faba Species 0.000 claims abstract description 12
- 235000002096 Vicia faba var. equina Nutrition 0.000 claims abstract description 12
- 235000013305 food Nutrition 0.000 claims description 26
- 238000010438 heat treatment Methods 0.000 claims description 21
- 230000000694 effects Effects 0.000 abstract description 21
- 238000004519 manufacturing process Methods 0.000 abstract description 13
- 240000003291 Armoracia rusticana Species 0.000 abstract description 9
- 235000011330 Armoracia rusticana Nutrition 0.000 abstract description 9
- 238000002156 mixing Methods 0.000 abstract description 5
- 239000000047 product Substances 0.000 description 75
- 150000001875 compounds Chemical class 0.000 description 33
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- 239000000203 mixture Substances 0.000 description 21
- 239000004480 active ingredient Substances 0.000 description 17
- 238000012545 processing Methods 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 239000002904 solvent Substances 0.000 description 14
- 238000000034 method Methods 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 10
- 150000008442 polyphenolic compounds Chemical class 0.000 description 10
- 235000013824 polyphenols Nutrition 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000002292 Radical scavenging effect Effects 0.000 description 9
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 208000027866 inflammatory disease Diseases 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000006227 byproduct Substances 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 238000000227 grinding Methods 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 238000002211 ultraviolet spectrum Methods 0.000 description 8
- 235000013311 vegetables Nutrition 0.000 description 8
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 7
- 235000010469 Glycine max Nutrition 0.000 description 7
- 244000068988 Glycine max Species 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 6
- 241000131500 Chionoecetes opilio Species 0.000 description 5
- 229940125904 compound 1 Drugs 0.000 description 5
- 235000013325 dietary fiber Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 241000195955 Equisetum hyemale Species 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 108010073771 Soybean Proteins Proteins 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 235000011888 snacks Nutrition 0.000 description 3
- 235000013322 soy milk Nutrition 0.000 description 3
- 238000002137 ultrasound extraction Methods 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241001098054 Pollachius pollachius Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000219793 Trifolium Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003579 anti-obesity Effects 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 150000002515 isoflavone derivatives Chemical class 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 238000004898 kneading Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
- 230000003405 preventing effect Effects 0.000 description 2
- 235000005974 protein supplement Nutrition 0.000 description 2
- 229940116540 protein supplement Drugs 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000019710 soybean protein Nutrition 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 241000722818 Aralia Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241001454443 Aruncus dioicus Species 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000005135 Micromeria juliana Nutrition 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 1
- NTNWOCRCBQPEKQ-UHFFFAOYSA-N NG-mono-methyl-L-arginine Natural products CN=C(N)NCCCC(N)C(O)=O NTNWOCRCBQPEKQ-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 240000002114 Satureja hortensis Species 0.000 description 1
- 235000007315 Satureja hortensis Nutrition 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000006045 Spondylarthropathies Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000002034 butanolic fraction Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- 235000013410 fast food Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 1
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 1
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 1
- 239000002044 hexane fraction Substances 0.000 description 1
- 238000001511 high performance liquid chromatography nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000005963 oophoritis Diseases 0.000 description 1
- 201000005737 orchitis Diseases 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/24—Heat, thermal treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medical Informatics (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본원에는 항산화, 항염 및/또는 면역증진 효과를 갖는 눈개승마와 콩비지의 복합 가공물 및 이의 제조방법이 개시된다. 상기 복합 가공물은 눈개승마와 콩비지가 함께 열처리된 것이고, 바이닐카테콜을 포함한다. 상기 복합 가공물은 눈개승마 단독 가공물에 비해 더욱 증진된 항산화, 항염 및/또는 면역증진 효과를 제공할 수 있다. 또한, 상기 제조방법은 눈개승마와 콩비지를 혼합하는 단계; 및 상기 혼합된 눈개승마와 콩비지를 함께 열처리하는 단계를 포함한다.Disclosed herein is a composite processed product of nungaeseungma and soybean curd, which has antioxidant, anti-inflammatory and/or immune-enhancing effects, and a method for producing the same. The composite processed product is heat-treated together with snow-covered horseradish and soybean curd, and contains vinyl catechol. The composite processed product can provide more enhanced antioxidant, anti-inflammatory and/or immune-enhancing effects compared to the single processed product. In addition, the manufacturing method includes the steps of mixing nungaeseungma and soybean curd; And it includes the step of heat-treating the mixed snow horse riding horse and soybean curd together.
Description
본원에는 항산화, 항염 및/또는 면역증진 효과를 갖는 눈개승마와 콩비지의 복합 가공물 및 이의 제조방법이 개시된다.Disclosed herein is a composite processed product of nungaeseungma and soybean curd, which has antioxidant, anti-inflammatory and/or immune-enhancing effects, and a method for producing the same.
산채에는 수용성 식이섬유, 비타민 C, 비타민 B, 무기질 함량이 풍부하며, 항산화 활성이 뛰어난 폴리페놀과 플라보노이드는 물론, 클로로필, 카로티노이드 등의 색소가 다량 함유되어 있다. 대부분의 산채를 섭취할 때 생체로 먹기에는 억세거나 질겨서 식감이 좋지 않고 산채 고유의 쓴 맛을 줄이기 위해 데쳐서 먹는 경우가 많다. 또한, 산채를 장기간 보관하기 위해 데친 후 말리거나 냉동보관을 한다. 그러나, 산채를 물에 데치게 되면 산채의 수용성 성분이 대부분 물로 빠져나오게 되고, 그로 인해 산채 자체의 약리활성이 떨어지는 단점이 있다.Wild vegetables are rich in soluble dietary fiber, vitamin C, vitamin B, and minerals, and contain large amounts of polyphenols and flavonoids with excellent antioxidant activity, as well as pigments such as chlorophyll and carotenoids. When consuming most wild vegetables, they are too tough or tough to eat raw and do not have a good texture, so they are often boiled to reduce the inherent bitter taste of the wild vegetables. Additionally, in order to store wild vegetables for a long period of time, they are blanched and then dried or frozen. However, when wild vegetables are boiled in water, most of the water-soluble components of the wild vegetables are released into the water, which has the disadvantage of reducing the pharmacological activity of the wild vegetables themselves.
한편, 국내에서 두부 제조를 위해 사용되는 콩은 연간 약 16만 톤으로 집계된다. 이 중 부산물로 얻어지는 콩비지는 약 80%의 수분을 함유하여 원료 대두의 약 1.3~1.5배 정도의 중량이 되므로 두부를 제조할 때 부산물로 남는 콩비지의 양은 약 24만 톤으로 추정된다. 콩비지는 영양학적으로 다른 부산물보다 풍부한 식이섬유와 영양소를 함유하고 있으나, 그 일부가 찌개로 활용되고 있을 뿐 수분 함량이 높아 유통 및 보관의 문제로 인해 대부분이 동물의 사료로 쓰이거나 버려지고 있어 이에 따른 활용도가 요구되고 있다.Meanwhile, the soybeans used to make tofu in Korea are estimated at approximately 160,000 tons per year. Among these, the okara obtained as a by-product contains about 80% moisture and weighs about 1.3 to 1.5 times the weight of the raw soybean, so the amount of okara remaining as a by-product when making tofu is estimated to be about 240,000 tons. Nutritionally, okara contains more dietary fiber and nutrients than other by-products, but only a portion of it is used as stew, and due to problems with distribution and storage due to its high moisture content, most of it is used as animal feed or discarded. There is a demand for appropriate utilization.
일 측면에서, 본 개시물은 카페익산과 바이닐카테콜 성분을 함유하는 눈개승마와 콩비지의 복합 가공물을 제공하는 것을 목적으로 한다.In one aspect, the present disclosure aims to provide a composite processed product of nungaeseungma and soybean curd containing caffeic acid and vinylcatechol components.
다른 측면에서, 본 개시물은 눈개승마와 콩비지의 복합 가공물을 유효성분으로 포함하는 항산화용 조성물을 제공하는 것을 목적으로 한다.In another aspect, the purpose of the present disclosure is to provide an anti-oxidant composition containing a complex processed product of nungaeseungma and soybean curd as an active ingredient.
또 다른 측면에서, 본 개시물은 눈개승마와 콩비지의 복합 가공물을 유효성분으로 포함하는 항염용 조성물을 제공하는 것을 목적으로 한다.In another aspect, the purpose of the present disclosure is to provide an anti-inflammatory composition containing a complex processed product of nungaeseungma and soybean curd as an active ingredient.
다른 측면에서, 본 개시물은 눈개승마와 콩비지의 복합 가공물을 유효성분으로 포함하는 면역증진용 조성물을 제공하는 것을 목적으로 한다.In another aspect, the purpose of the present disclosure is to provide a composition for enhancing immunity containing a complex processed product of nungaeseungma and soybean curd as an active ingredient.
다른 측면에서, 본 개시물은 눈개승마와 콩비지의 복합 가공물을 포함하는 식품을 제공하는 것을 목적으로 한다.In another aspect, the present disclosure aims to provide a food containing a complex processed product of snow crab and soybean curd.
다른 측면에서, 본 개시물은 눈개승마와 콩비지의 복합 가공물을 제조하는 방법을 제공하는 것을 목적으로 한다.In another aspect, the purpose of the present disclosure is to provide a method for producing a composite product of snow horse riding horse and soybean curd.
일 측면에서, 본 개시물은 복합 가공물이고, 상기 복합 가공물은 눈개승마와 콩비지가 함께 열처리된 것이고, 상기 복합 가공물은 바이닐카테콜을 포함하는 것인, 눈개승마와 콩비지의 복합 가공물을 제공한다.In one aspect, the present disclosure is a composite product, wherein the composite product is heat-treated together with snow-covered horseradish and soybean curd, and the composite product includes vinyl catechol.
예시적인 일 구현예에서, 상기 열처리는 오토클레이브에서 실시하는 것일 수 있다.In an exemplary embodiment, the heat treatment may be performed in an autoclave.
예시적인 일 구현예에서, 상기 열처리는 80 내지 120 ℃에서 실시하는 것일 수 있다.In an exemplary embodiment, the heat treatment may be performed at 80 to 120 °C.
예시적인 일 구현예에서, 상기 열처리는 5분 내지 60분 동안 실시하는 것일 수 있다.In one exemplary embodiment, the heat treatment may be performed for 5 to 60 minutes.
예시적인 일 구현예에서, 상기 눈개승마와 콩비지는 1 : 0.1 내지 10의 중량비로 혼합되어 함께 열처리된 것일 수 있다.In an exemplary embodiment, the snow horse riding horse and the soybean curd may be mixed at a weight ratio of 1:0.1 to 10 and heat-treated together.
예시적인 일 구현예에서, 상기 눈개승마와 콩비지는 1 : 0.1 내지 0.5의 중량비로 혼합되어 함께 열처리된 것일 수 있다.In an exemplary embodiment, the snow crab and soybean curd may be mixed at a weight ratio of 1:0.1 to 0.5 and heat-treated together.
다른 측면에서, 본 개시물은 상기 눈개승마와 콩비지의 복합 가공물을 유효성분으로 포함하는 항산화용 조성물을 제공한다.In another aspect, the present disclosure provides an anti-oxidant composition containing the complex processed product of the above-mentioned nungaeseungma and soybean curd as an active ingredient.
또 다른 측면에서, 본 개시물은 상기 눈개승마와 콩비지의 복합 가공물을 유효성분으로 포함하는 항염용 조성물을 제공한다.In another aspect, the present disclosure provides an anti-inflammatory composition comprising the complex processed product of the above-mentioned nungaeseungma and soybean curd as an active ingredient.
또 다른 측면에서, 본 개시물은 상기 눈개승마와 콩비지의 복합 가공물을 유효성분으로 포함하는 면역증진용 조성물을 제공한다.In another aspect, the present disclosure provides a composition for enhancing immunity containing the complex processed product of the above-mentioned nungaeseungma and soybean curd as an active ingredient.
또 다른 측면에서, 본 개시물은 상기 눈개승마와 콩비지의 복합 가공물을 포함하는 식품을 제공한다.In another aspect, the present disclosure provides a food product comprising a composite processed product of the above-mentioned nungaeseungma and soybean curd.
또 다른 측면에서, 본 개시물은 상기 눈개승마와 콩비지의 복합 가공물을 제조하는 방법으로, 눈개승마와 콩비지를 혼합하는 단계; 및 상기 혼합된 눈개승마와 콩비지를 함께 열처리하는 단계를 포함하는, 눈개승마와 콩비지의 복합 가공물을 제조하는 방법을 제공한다.In another aspect, the present disclosure is a method of manufacturing a composite product of the snow horse riding horse and soybean curd, comprising the steps of mixing snow horse riding horse and soybean curd; And it provides a method of producing a composite processed product of snow clover and soybean curd, comprising the step of heat-treating the mixed snow pollack and soybean curd together.
일 측면에서, 본 개시물에 개시된 기술은 카페익산과 바이닐카테콜 성분을 함유하는 눈개승마와 콩비지의 복합 가공물을 제공하는 효과가 있다.In one aspect, the technology disclosed in the present disclosure has the effect of providing a composite processed product of nungaeseungma and soybean curd containing caffeic acid and vinyl catechol components.
다른 측면에서, 본 개시물에 개시된 기술은 눈개승마와 콩비지의 복합 가공물을 유효성분으로 포함하는 항산화용 조성물을 제공하는 효과가 있다.In another aspect, the technology disclosed in the present disclosure has the effect of providing an anti-oxidant composition containing a complex processed product of nungaeseungma and soybean curd as an active ingredient.
또 다른 측면에서, 본 개시물에 개시된 기술은 눈개승마와 콩비지의 복합 가공물을 유효성분으로 포함하는 항염용 조성물을 제공하는 효과가 있다.In another aspect, the technology disclosed in the present disclosure has the effect of providing an anti-inflammatory composition containing a complex processed product of snow horse riding horse and soybean curd as an active ingredient.
다른 측면에서, 본 개시물에 개시된 기술은 눈개승마와 콩비지의 복합 가공물을 유효성분으로 포함하는 면역증진용 조성물을 제공하는 효과가 있다.In another aspect, the technology disclosed in the present disclosure has the effect of providing an immune-boosting composition containing a complex processed product of nungaeseungma and soybean curd as an active ingredient.
다른 측면에서, 본 개시물에 개시된 기술은 눈개승마와 콩비지의 복합 가공물을 포함하는 식품을 제공하는 효과가 있다.In another aspect, the technology disclosed in the present disclosure has the effect of providing a food containing a complex processed product of nungaeseungma and soybean curd.
다른 측면에서, 본 개시물에 개시된 기술은 눈개승마와 콩비지의 복합 가공물을 제조하는 방법을 제공하는 효과가 있다.In another aspect, the technology disclosed in the present disclosure has the effect of providing a method for manufacturing a composite product of snow horse riding horse and soybean curd.
도 1은 본 개시물의 일 실시예에 따른 콩비지와의 융합 열가공을 통한 눈개승마 폴리페놀 성분 변화를 나타낸 것이다.
도 2는 본 개시물의 일 비교예에 따른 눈개승마 가공물의 가공 온도 (100, 110℃) 및 시간 (10, 20, 30min)에 따른 HPLC-ABTS 크로마토그램 (Positive peak; 254nm, Negative peak; 734nm)을 나타낸 것이다. AD는 열가공하지 않은 눈개승마 시료를 의미하며, 열가공한 눈개승마 가공물은 AD_AC1으로 표기하였다.
도 3은 본 개시물의 일 비교예에 따른 눈개승마 가공물의 가공 온도 (100, 110℃) 및 시간 (10, 20, 30min)에 따른 항산화 성분 증감 비율을 HPLC 크로마토그램에서의 피크 면적값을 이용하여 나타낸 것이다.
도 4는 본 개시물의 일 비교예에 따른 눈개승마 가공물의 가공 온도 (100, 110℃) 및 시간 (10, 20, 30min)에 따른 DPPH 라디칼 소거 활성을 나타낸 것이다.
도 5는 본 개시물의 일 실시예에 따른 눈개승마와 콩비지의 복합 가공물에 대한 HPLC-ABTS 크로마토그램 (Positive peak; 254nm, Negative peak; 734nm)을 나타낸 것이다. AD는 열가공하지 않은 눈개승마 시료를 의미하며, 열가공한 복합 가공물은 AD_SCR_AC1으로 표기하였다. AD_AC1은 100 ℃에서 10분 동안 단독 열가공한 눈개승마 가공물, SCR_AC1은 100 ℃에서 10분 동안 단독 열가공한 콩비지 가공물을 의미한다.
도 6은 본 개시물의 일 실시예에 따른 눈개승마와 콩비지의 복합 가공물에 대한 항산화 성분 증감 비율을 HPLC 크로마토그램에서의 피크 면적값을 이용하여 나타낸 것이다.
도 7은 본 개시물의 일 비교예 및 실시예에 따른 가공물의 세포 독성 평가 결과를 나타낸 것이다.
도 8은 본 개시물의 일 실시예에 따른 눈개승마와 콩비지의 복합 가공물에 대한 NO assay 결과를 나타낸 것이다.
도 9는 본 개시물의 일 실험예에 따른 눈개승마 추출물로부터 화합물을 분리한 모식도를 나타낸 것이다.
도 10은 본 개시물의 일 실험예에 따른 눈개승마 추출물과 분획물들의 HPLC 크로마토그램 (254nm)을 나타낸 것이다.
도 11은 본 개시물의 일 실험예에 따른 눈개승마 추출물과 분획물들의 DPPH 라디칼 소거 활성을 나타낸 것이다.
도 12는 본 개시물의 일 실험예에 따른 눈개승마의 EA 분획물과 SPE 분획물들의 HPLC 크로마토그램 (254nm)을 나타낸 것이다.
도 13은 화합물 1의 UV 스펙트럼을 나타낸 것이다.
도 14는 화합물 1의 HPLC-MS 스펙트럼을 나타낸 것이다.
도 15는 화합물 1의 1H NMR 스펙트럼 (methanol-d₄)을 나타낸 것이다.
도 16은 화합물 2의 UV 스펙트럼을 나타낸 것이다.
도 17은 화합물 2의 HPLC-MS 스펙트럼을 나타낸 것이다.
도 18은 화합물 3의 UV 스펙트럼을 나타낸 것이다.
도 19는 화합물 3의 HPLC-MS 스펙트럼을 나타낸 것이다.
도 20은 화합물 4의 UV 스펙트럼을 나타낸 것이다.
도 21은 화합물 4의 HPLC-MS 스펙트럼을 나타낸 것이다.
도 22는 화합물 4의 1H NMR 스펙트럼 (methanol-d₄)을 나타낸 것이다.
도 23은 화합물 4의 1H-1H COSY NMR 스펙트럼 (methanol-d₄)을 나타낸 것이다.
도 24는 화합물 4의 1H-13C HSQC NMR 스펙트럼 (methanol- d₄)을 나타낸 것이다.
도 25는 화합물 4의 1H-13C HMBC NMR 스펙트럼 (methanol-d₄)을 나타낸 것이다.Figure 1 shows the change in the polyphenol component of nungaeseungma through fusion heat processing with soybean curd according to an embodiment of the present disclosure.
Figure 2 is an HPLC-ABTS chromatogram (Positive peak; 254nm, Negative peak; 734nm) according to processing temperature (100, 110°C) and time (10, 20, 30min) of a snow horse riding product according to a comparative example of the present disclosure. It represents. AD refers to the non-heat-processed snow horse riding sample, and the heat-processed snow horse riding product is denoted as AD_AC1.
Figure 3 shows the increase/decrease rate of antioxidant components according to the processing temperature (100, 110°C) and time (10, 20, 30 min) of the snow horse riding product according to a comparative example of the present disclosure using the peak area value in the HPLC chromatogram. It is shown.
Figure 4 shows the DPPH radical scavenging activity according to processing temperature (100, 110°C) and time (10, 20, 30 min) of a snow horse riding product according to a comparative example of the present disclosure.
Figure 5 shows an HPLC-ABTS chromatogram (Positive peak; 254 nm, Negative peak; 734 nm) for a composite product of snow crab and soybean curd according to an embodiment of the present disclosure. AD refers to the non-heat-processed snow horse riding sample, and the heat-processed composite product is marked as AD_SCR_AC1. AD_AC1 refers to a processed snow horse riding product that was individually heat-processed at 100°C for 10 minutes, and SCR_AC1 refers to a soybean curd product that was individually heat-processed at 100°C for 10 minutes.
Figure 6 shows the increase/decrease ratio of antioxidant components for the composite processed product of nungaeseungma and soybean curd according to an embodiment of the present disclosure using the peak area value in the HPLC chromatogram.
Figure 7 shows the results of cytotoxicity evaluation of the processed product according to a comparative example and example of the present disclosure.
Figure 8 shows the NO assay results for a composite product of nungaeseungma and soybean curd according to an embodiment of the present disclosure.
Figure 9 shows a schematic diagram of the separation of compounds from the extract of Snowy Horsetail according to an experimental example of the present disclosure.
Figure 10 shows an HPLC chromatogram (254 nm) of the extract and fractions of Siberian horsetail according to an experimental example of the present disclosure.
FIG. 11 shows the DPPH radical scavenging activity of the extract and fractions of Siberian horsetail according to an experimental example of the present disclosure.
Figure 12 shows an HPLC chromatogram (254 nm) of the EA fraction and SPE fraction of snow-covered horsetail according to an experimental example of the present disclosure.
Figure 13 shows the UV spectrum of Compound 1.
Figure 14 shows the HPLC-MS spectrum of Compound 1.
Figure 15 shows the 1 H NMR spectrum of compound 1 (methanol- d ₄).
Figure 16 shows the UV spectrum of Compound 2.
Figure 17 shows the HPLC-MS spectrum of Compound 2.
Figure 18 shows the UV spectrum of compound 3.
Figure 19 shows the HPLC-MS spectrum of compound 3.
Figure 20 shows the UV spectrum of Compound 4.
Figure 21 shows the HPLC-MS spectrum of compound 4.
Figure 22 shows the 1 H NMR spectrum of compound 4 (methanol- d ₄).
Figure 23 shows the 1 H- 1 H COZY NMR spectrum (methanol- d ₄) of compound 4.
Figure 24 shows the 1 H- 13 C HSQC NMR spectrum of compound 4 (methanol- d ₄).
Figure 25 shows the 1 H- 13 C HMBC NMR spectrum (methanol- d ₄) of compound 4.
이하, 본 개시물을 상세히 설명한다.Hereinafter, the present disclosure will be described in detail.
일 측면에서, 본 개시물은 복합 가공물이고, 상기 복합 가공물은 눈개승마와 콩비지가 함께 열처리된 것이고, 상기 복합 가공물은 바이닐카테콜을 포함하는 것인, 눈개승마와 콩비지의 복합 가공물을 제공한다.In one aspect, the present disclosure is a composite product, wherein the composite product is heat-treated together with snow-covered horseradish and soybean curd, and the composite product includes vinyl catechol.
예시적인 일 구현예에서, 상기 복합 가공물은 바이닐카테콜과 카페익산을 포함하는 것일 수 있다.In one exemplary embodiment, the composite processed product may include vinyl catechol and caffeic acid.
일 측면에서, 본 개시물에 개시된 기술은 눈개승마를 물 속에 넣어 데치지 않고 가열된 수증기로 간접적으로 가열하는 방식을 통해 영양 손실이 적을 뿐만 아니라 온도가 고르게 분포되어 단시간 내에 효과적으로 열가공할 수 있으며 가공물의 모양을 보존할 수 있는 눈개승마와 콩비지의 복합 가공물을 제공한다.In one aspect, the technology disclosed in the present disclosure not only reduces nutritional loss through a method of indirectly heating snow horse riding with heated steam rather than boiling it in water, but the temperature is evenly distributed, enabling effective heat processing in a short period of time. We provide a composite processed product of nungaeseungma and soybean curd that can preserve the shape of the processed product.
다른 측면에서, 본 개시물에 개시된 기술은 눈개승마와 콩비지를 함께 열가공함으로써 눈개승마의 폴리페놀 성분의 파괴를 방지하고 폴리페놀의 단량화를 유도하여 항산화 활성을 증가시킬 수 있다. 또한, 눈개승마와 콩비지의 부족한 성분을 서로 보완하여 영양소의 불균형을 해결할 수 있다. 콩비지가 혼합되어 눈개승마의 쓴맛이 감소되고 감칠맛을 증가되어 눈개승마의 관능적 품질을 향상시켜 주는 효과가 있다.In another aspect, the technology disclosed in the present disclosure can prevent the destruction of the polyphenol component of the snow horseradish and induce monomerization of the polyphenol to increase antioxidant activity by heat processing the snow horseradish and the soybean curd together. In addition, nutrient imbalance can be resolved by complementing the missing ingredients of nungaeseungma and soybean curd. The mixture of soybean curd has the effect of reducing the bitterness of snow riding horse and increasing its savory taste, thereby improving the sensory quality of snow riding horse.
눈개승마 (Aruncus dioicus)는 장미과 (Rosaceae) 눈개승마속 (Aruncus)에 속해 있는 다년생 초본으로 전국의 고산지역에 분포하고 있다. 눈개승마는 인삼맛, 고기맛, 두릅맛이 나는 산채로, 동의보감에서는 맛이 달고 쓰며 독이 없는 식물로 사람의 기운을 올려주는 명약이라고 설명되어 있다. 울릉도에서는 고기나물로 불리우며, 예로부터 명절에 쇠고기국을 끓일 때 눈개승마를 이용해 왔다. 눈개승마의 어린순은 해열, 해독 등의 효과가 있다고 알려져 끓는 물에 데친 후 식용하거나 말려서 작은 잎을 제거한 후 식용하여 왔다. 이러한 눈개승마의 생리활성으로는 신장 손상 억제, 항산화, 암세포 생육 억제 활성, 항혈전, 항염, 멜라닌 합성 억제, 피부 노화 억제, 주름 개선, 항균, 항당뇨, 항비만, 면역증진 등 다양한 활성이 있는 것으로 알려져 있다. Aruncus dioicus is a perennial herb belonging to the genus Aruncus of the Rosaceae family and is distributed in alpine areas across the country. Nungaeseungma is a wild vegetable with the taste of ginseng, meat, and aralia. In Donguibogam, it is described as a sweet, bitter, non-poisonous plant that is an excellent medicine that boosts a person's energy. In Ulleungdo, it is called meat namul, and since ancient times, it has been used to make beef soup on holidays. The young shoots of the snow-covered horse are known to have fever-relieving and detoxifying effects. They have been blanched in boiling water and eaten, or dried and eaten after removing the small leaves. These physiological activities include kidney damage inhibition, antioxidant activity, cancer cell growth inhibition activity, anti-thrombosis, anti-inflammatory activity, inhibition of melanin synthesis, skin aging inhibition, wrinkle improvement, antibacterial activity, anti-diabetes, anti-obesity, and immune enhancement. It is known that
예시적인 일 구현예에서, 상기 눈개승마는 지상부를 사용한 것일 수 있다.In one exemplary embodiment, the snow dog riding may be made using an aerial part.
예시적인 일 구현예에서, 상기 눈개승마는 건조, 마쇄 및/또는 분쇄된 것일 수 있다.In one exemplary embodiment, the snow horse riding horse may be dried, ground, and/or ground.
예시적인 일 구현예에서, 상기 눈개승마는 플레이크, 파우더 등의 형태를 갖는 것일 수 있다.In one exemplary embodiment, the snow horse riding horse may have the form of flakes, powder, etc.
콩비지는 두부를 제조하는 공정에서 발생하는 부산물을 의미하는 것으로, 두부를 만들 때 두유를 짜고 남은 부산물인 것일 수 있다. 예를 들어, 상기 콩비지는 콩단백에서 두유를 짜고 남은 부산물을 의미하는 것으로, 상기 콩단백에서 수용성 단백질을 제거한 것일 수 있다. 본원에서 콩단백은 콩에서 기름을 빼고 남은 부산물을 의미한다.Bean curd refers to a by-product generated during the tofu manufacturing process, and may be a by-product left over from squeezing soy milk when making tofu. For example, the soybean curd refers to a by-product remaining after extracting soymilk from the soybean protein, and may be obtained by removing the water-soluble protein from the soybean protein. Here, soy protein refers to the by-product remaining after removing the oil from soybeans.
콩비지는 많은 양의 수용성 물질이 빠져 나간 상태이지만, 양질의 단백질과 풍부한 섬유소를 비롯해 인체에 필요한 영양성분들을 다량 함유하고 있다. 단백질 섭취량에 따른 체중 증가량의 비율을 나타내는 값인 단백질 효율비 (protein efficiency ratio, PER)가 대두, 두유 및 두부 중에서 가장 높은 우수한 단백질 자원이다. 또한, 콩비지는 여성 호르몬 에스트로겐과 유사 작용을 하는 이소플라본 (phytoestrogen)을 고함유하여 폐경기 증후군의 예방 및 치료에도 활용이 가능하다.Although a large amount of water-soluble substances have been removed from okara, it contains a large amount of nutrients necessary for the human body, including high-quality protein and abundant fiber. It is an excellent protein resource with the highest protein efficiency ratio (PER), which is a value representing the ratio of weight gain based on protein intake, among soybeans, soymilk, and tofu. In addition, okara is high in isoflavones (phytoestrogens), which act similarly to the female hormone estrogen, so it can be used to prevent and treat menopausal syndrome.
콩비지는 콩의 품종, 추출 방법, 분리 방법 등에 따라 다르지만, 예를 들어 건물량 기준으로 단백질 24~30 중량%, 지방 13~15 중량%, 탄수화물 50~60 중량%, 회분 4~5 중량%를 가져 수분을 제거하면 탄수화물과 단백질을 위주로 하는 유용한 식품 재료로 활용할 수 있다. 콩비지의 단백질은 다른 식품에는 부족한 황 함유 아미노산과 리신의 함량이 비교적 높아 양질의 단백질로 평가된다. 또한, 콩비지에는 두부에 거의 없는 식이섬유의 함량이 높아 식이섬유를 이용한 식품 재료로 활용할 수도 있다.Bean curd varies depending on the soybean variety, extraction method, separation method, etc., but for example, based on dry matter, it contains 24-30% by weight of protein, 13-15% by weight of fat, 50-60% by weight of carbohydrates, and 4-5% by weight of ash. If the moisture is removed, it can be used as a useful food ingredient mainly containing carbohydrates and proteins. The protein in okara is evaluated as a high-quality protein due to its relatively high content of sulfur-containing amino acids and lysine, which are lacking in other foods. In addition, okara has a high content of dietary fiber, which is almost absent in tofu, so it can be used as a food ingredient using dietary fiber.
예시적인 일 구현예에서, 상기 콩비지는 반죽, 성형, 건조, 마쇄, 분쇄, 추출, 발효 등의 추가적인 공정을 가하여 플레이크, 파우더, 액상, 고형물 등의 형태로 가공한 것일 수 있다.In one exemplary embodiment, the soybean curd may be processed into the form of flakes, powder, liquid, solid, etc. by applying additional processes such as kneading, molding, drying, grinding, grinding, extraction, and fermentation.
예시적인 일 구현예에서, 상기 콩비지는 건조 및 마쇄한 것일 수 있다.In one exemplary embodiment, the soybean curd may be dried and ground.
예시적인 일 구현예에서, 상기 콩비지는 두부 제조 후 남은 부산물을 열풍건조한 다음 분말화한 것일 수 있다.In one exemplary embodiment, the soybean curd may be obtained by hot-air drying the by-product remaining after manufacturing tofu and then powdering it.
예시적인 일 구현예에서, 상기 열처리는 습식 열처리하는 것일 수 있다.In one exemplary embodiment, the heat treatment may be wet heat treatment.
예시적인 일 구현예에서, 상기 열처리는 오토클레이브에서 실시하는 것일 수 있다.In an exemplary embodiment, the heat treatment may be performed in an autoclave.
낮은 온도에서 열처리하는 경우 열처리 시간이 증가하여 실효성이 떨어질 수 있고, 높은 온도에서 열처리하는 경우 폴리페놀 성분이 파괴될 수 있다. 따라서, 상기 열처리는 80 내지 120 ℃에서 실시하는 것이 바람직할 수 있다.If heat treated at a low temperature, the heat treatment time may increase and the effectiveness may be reduced, and if heat treated at a high temperature, the polyphenol component may be destroyed. Therefore, it may be desirable to carry out the heat treatment at 80 to 120 °C.
예시적인 일 구현예에서, 상기 열처리는 80 ℃ 이상, 85 ℃ 이상, 90 ℃ 이상, 95 ℃ 이상 또는 100 ℃ 이상이고, 120 ℃ 이하, 115 ℃ 이하, 110 ℃ 이하, 105 ℃ 이하 또는 100 ℃ 이하인 온도에서 실시하는 것일 수 있다,In an exemplary embodiment, the heat treatment is 80°C or higher, 85°C or higher, 90°C or higher, 95°C or higher, or 100°C or lower, and 120°C or lower, 115°C or lower, 110°C or lower, 105°C or lower, or 100°C or lower. It may be carried out at temperature,
예시적인 일 구현예에서, 상기 열처리는 95 내지 105 ℃, 100 내지 105 ℃, 또는 100 ℃에서 실시하는 것이 더 바람직할 수 있다.In an exemplary embodiment, the heat treatment may be more preferably performed at 95 to 105 °C, 100 to 105 °C, or 100 °C.
예시적인 일 구현예에서, 상기 열처리는 5분 내지 60분 동안 실시하는 것일 수 있다. 다른 예시적인 일 구현예에서, 상기 열처리는 5분 이상, 6분 이상, 7분 이상, 8분 이상, 9분 이상 또는 10분 이상이고 60분 이하, 55분 이하, 50분 이하, 45분 이하, 40분 이하, 35분 이하, 30분 이하, 25분 이하, 20분 이하, 15분 이하, 14분 이하, 13분 이하, 12분 이하, 11분 이하 또는 10분 이하의 시간 동안 실시하는 것일 수 있다.In one exemplary embodiment, the heat treatment may be performed for 5 to 60 minutes. In another exemplary embodiment, the heat treatment is 5 minutes or more, 6 minutes or more, 7 minutes or more, 8 minutes or more, 9 minutes or more, or 10 minutes or more, and 60 minutes or less, 55 minutes or less, 50 minutes or less, 45 minutes or less. , conducted for 40 minutes or less, 35 minutes or less, 30 minutes or less, 25 minutes or less, 20 minutes or less, 15 minutes or less, 14 minutes or less, 13 minutes or less, 12 minutes or less, 11 minutes or less, or 10 minutes or less. You can.
예시적인 일 구현예에서, 상기 열처리는 80 내지 110 ℃에서 5분 내지 30분, 또는 100 ℃에서 10분 동안 실시하는 것이 바람직할 수 있다.In an exemplary embodiment, the heat treatment may be preferably performed at 80 to 110°C for 5 to 30 minutes, or at 100°C for 10 minutes.
예시적인 일 구현예에서, 상기 눈개승마와 콩비지는 1 : 0.1 내지 10의 중량비로 혼합되어 함께 열처리된 것이 항산화, 항염 및/또는 면역증진 효과에 있어서 바람직할 수 있다. In an exemplary embodiment, it may be preferable for the eye-gae-seung-ma and soybean curd to be mixed and heat-treated together at a weight ratio of 1:0.1 to 10 for antioxidant, anti-inflammatory and/or immune-enhancing effects.
예시적인 일 구현예에서, 상기 눈개승마와 콩비지는 1 : 0.1 내지 0.5의 중량비로 혼합되어 함께 열처리된 것일 수 있다.In an exemplary embodiment, the snow crab and soybean curd may be mixed at a weight ratio of 1:0.1 to 0.5 and heat-treated together.
예시적인 일 구현예에서, 상기 눈개승마와 콩비지는 1 : 0.4 내지 0.6의 중량비 또는 1 : 0.5의 중량비로 혼합되어 함께 열처리된 것이 눈개승마의 폴리페놀 성분 증진 효과에 있어서 바람직할 수 있다.In an exemplary embodiment, it may be preferable that the snow horse riding horse and soybean curd are mixed and heat-treated together at a weight ratio of 1:0.4 to 0.6 or a weight ratio of 1:0.5 in terms of the effect of enhancing the polyphenol component of snow horse riding horse.
본원에 개시된 눈개승마와 콩비지의 복합 가공물은 눈개승마와 콩비지가 함께 열처리됨으로써, 바람직하게는 80 내지 110 ℃에서 5분 내지 30분 동안 열처리됨으로써 눈개승마에 함유된 카페익산 함량이 증진될 뿐만 아니라 바이닐카테콜이 다량 생성되어 우수한 항산화, 항염 및/또는 면역증진 효과를 제공한다. The composite processed product of snowy horse riding and soybean curd disclosed herein is heat treated together with snowy horse riding and soybean curd, preferably at 80 to 110° C. for 5 to 30 minutes, so that not only the caffeic acid content contained in the snowy horse riding is increased, but also the vinyl Catechol is produced in large quantities, providing excellent antioxidant, anti-inflammatory and/or immune-boosting effects.
예시적인 일 구현예에서, 상기 바이닐카테콜은 하기 화학식 4를 갖는 4-바이닐카테콜인 것일 수 있다.In an exemplary embodiment, the vinyl catechol may be 4-vinyl catechol having the formula 4 below.
[화학식 4][Formula 4]
예시적인 일 구현예에서, 상기 눈개승마와 콩비지의 복합 가공물은 열처리 후 반죽, 성형, 건조, 마쇄, 분쇄, 추출, 발효 등의 추가적인 공정을 가하여 플레이크, 파우더, 액상, 고형물 등의 형태로 가공된 것일 수 있다.In an exemplary embodiment, the composite processed product of the nungaeseungma and the soybean curd is processed into the form of flakes, powder, liquid, solid, etc. by applying additional processes such as kneading, molding, drying, grinding, grinding, extraction, and fermentation after heat treatment. It may be.
다른 측면에서, 본 개시물은 상기 눈개승마와 콩비지의 복합 가공물을 유효성분으로 포함하는 항산화용 조성물을 제공한다. 본원에 개시된 복합 가공물은 눈개승마를 콩비지와 융합 열가공함으로써 새로운 항산화 성분을 생성시켜 눈개승마를 적은 양으로 사용하여도 우수한 항산화 효능을 제공할 수 있다.In another aspect, the present disclosure provides an anti-oxidant composition containing the complex processed product of the above-mentioned nungaeseungma and soybean curd as an active ingredient. The composite processed product disclosed herein generates new antioxidant ingredients by fusing and heat-processing nungaeseungma with soybean curd, and can provide excellent antioxidant efficacy even when using a small amount of nungaeseungma.
본 개시물에서 항산화는 산화 과정을 예방, 억제, 저해, 개선 및/또는 지연시키는 효능을 의미한다. In the present disclosure, antioxidant refers to the effect of preventing, inhibiting, inhibiting, improving and/or delaying oxidation processes.
또 다른 측면에서, 본 개시물은 상기 눈개승마와 콩비지의 복합 가공물을 유효성분으로 포함하는 항염용 조성물을 제공한다.In another aspect, the present disclosure provides an anti-inflammatory composition comprising the complex processed product of the above-mentioned nungaeseungma and soybean curd as an active ingredient.
본 개시물에서 항염은 염증 및/또는 염증 관련 질환을 예방, 억제, 저해, 개선 및/또는 치료하는 효능을 의미하는 것으로서, 염증은 체액이 조직 세포 사이에 증가하여 나타나는 부종, 혈관 확장에 따른 충혈, 발열 물질과 혈관 확장에 의한 발열, 아라키돈산 대사산물에 의한 통증 등과 같은 증상 또는 징후로 나타나고, 시간에 따라 급성, 아급성, 만성 염증질환으로 분류할 수 있고, 병태 생리에 따라 감염성, 알레르기성, 자가면역성, 독성, 대사성, 외상성 염증질환으로 분류할 수 있다.In the present disclosure, anti-inflammatory refers to the efficacy of preventing, suppressing, inhibiting, improving and/or treating inflammation and/or inflammation-related diseases. Inflammation refers to edema caused by an increase in body fluid between tissue cells and hyperemia caused by vasodilation. It appears as symptoms or signs such as fever due to pyrogenic substances and vasodilation, pain due to arachidonic acid metabolites, etc., and can be classified into acute, subacute, and chronic inflammatory diseases depending on time, and infectious and allergic depending on the pathophysiology. , can be classified into autoimmune, toxic, metabolic, and traumatic inflammatory diseases.
예시적인 일 구현예에서, 상기 염증은 비염, 부비동염, 중이염, 비인두염, 후두염, 기관지염, 천식, 만성폐쇄성폐질환, 기관지확장증, 세기관지염, 폐렴, 폐섬유화증 등의 호흡기계 염증질환; 구강염, 식도염, 위염, 소화성궤양, 과민성장증후군, 염증성장질환, 담낭염, 담도염, 췌장염, 간염 등의 소화기계 염증질환; 여드름, 접촉성 피부염, 지루성 피부염, 아토피 피부염, 건선 등의 피부 염증질환; 심내막염, 심근염, 심낭염, 혈관염, 동맥경화증, 패혈증 등의 심혈관계 염증질환; 갑상선염, 부갑상산염, 당뇨병 등의 내분비계 염증질환; 사구체신염, 신병증, 간질성 신질환, 고환염, 난소염, 자궁내막염, 질염 등의 비뇨생식계 염증질환; 류마티스관절염, 척추관절병증, 골관절염, 통풍, 전신성홍반성루프스, 전신성경화증, 근병증, 쇼그렌증후군, 베체트병, 항인지질증후군 등의 근골격계 염증질환; 혈관성치매, 알츠하이머병, 퇴행성뇌질환, 우울증, 정신분열증 등의 신경정신계 염증질환 등으로 이루어진 군으로부터 선택될 수 있다.In an exemplary embodiment, the inflammation includes respiratory tract inflammatory diseases such as rhinitis, sinusitis, otitis media, nasopharyngitis, laryngitis, bronchitis, asthma, chronic obstructive pulmonary disease, bronchiectasis, bronchiolitis, pneumonia, and pulmonary fibrosis; Inflammatory diseases of the digestive system such as stomatitis, esophagitis, gastritis, peptic ulcer, irritable bowel syndrome, inflammatory bowel disease, cholecystitis, cholangitis, pancreatitis, and hepatitis; Skin inflammatory diseases such as acne, contact dermatitis, seborrheic dermatitis, atopic dermatitis, and psoriasis; Cardiovascular inflammatory diseases such as endocarditis, myocarditis, pericarditis, vasculitis, arteriosclerosis, and sepsis; Endocrine inflammatory diseases such as thyroiditis, parathyroidism, and diabetes; Urogenital inflammatory diseases such as glomerulonephritis, nephropathy, interstitial kidney disease, orchitis, oophoritis, endometritis, and vaginitis; Musculoskeletal inflammatory diseases such as rheumatoid arthritis, spondyloarthropathy, osteoarthritis, gout, systemic lupus erythematosus, systemic sclerosis, myopathy, Sjögren's syndrome, Behcet's disease, and antiphospholipid syndrome; It may be selected from the group consisting of neuropsychiatric inflammatory diseases such as vascular dementia, Alzheimer's disease, degenerative brain disease, depression, and schizophrenia.
또 다른 측면에서, 본 개시물은 상기 눈개승마와 콩비지의 복합 가공물을 유효성분으로 포함하는 면역증진용 조성물을 제공한다.In another aspect, the present disclosure provides a composition for enhancing immunity containing the complex processed product of the above-mentioned nungaeseungma and soybean curd as an active ingredient.
본 개시물에서 유효성분은 단독으로 목적으로 하는 활성을 나타내거나 또는 그 자체는 활성이 없는 담체 등과 함께 목적으로 하는 활성을 나타낼 수 있는 성분을 의미한다.In the present disclosure, an active ingredient refers to an ingredient that can exhibit the desired activity alone or in combination with a carrier that is inactive on its own.
예시적인 일 구현예에서, 상기 조성물은 식품 조성물인 것일 수 있다.In one exemplary embodiment, the composition may be a food composition.
예시적인 일 구현예에서, 상기 조성물은 화장료 조성물인 것일 수 있다.In one exemplary embodiment, the composition may be a cosmetic composition.
예시적인 일 구현예에서, 상기 조성물은 눈개승마의 항산화, 항염, 미백, 주름 개선 활성을 이용한 기능성 화장료 조성물인 것일 수 있다.In an exemplary embodiment, the composition may be a functional cosmetic composition using the antioxidant, anti-inflammatory, whitening, and wrinkle-improving activities of snow horse riding horse.
또 다른 측면에서, 본 개시물은 상기 눈개승마와 콩비지의 복합 가공물을 포함하는 식품을 제공한다. 예컨대, 비건 식품, 단백질 보충용 식품, 간편 식품, 스포츠 또는 에너지용 식품, 다이어트 식품, 간식 식품, 냉동 식품, 어린이 성장용 식품, 수험생 식품, 노인 근육 강화 식품 등의 다양한 식품을 제조할 수 있다.In another aspect, the present disclosure provides a food product comprising a composite processed product of the above-mentioned nungaeseungma and soybean curd. For example, various foods such as vegan food, protein supplement food, convenience food, sports or energy food, diet food, snack food, frozen food, food for children's growth, food for test takers, and muscle strengthening food for the elderly can be manufactured.
예시적인 일 구현예에서, 상기 식품은 스낵, 시리얼, 면, 빵, 선식, 아이스크림, 빙과, 콩고기, 음료, 사탕, 초콜릿 및 젤리로 이루어진 군에서 선택되는 1 이상인 것일 수 있다.In an exemplary embodiment, the food may be one or more selected from the group consisting of snacks, cereals, noodles, bread, snacks, ice cream, frozen desserts, soybean meat, beverages, candy, chocolate, and jelly.
예시적인 일 구현예에서, 상기 식품은 건강기능식품인 것일 수 있다.In an exemplary embodiment, the food may be a health functional food.
예시적인 일 구현예에서, 상기 식품은 콩비지의 이소플라본과 단백질을 이용한 여성호르몬제, 단백질보충제 등의 건강기능식품인 것일 수 있다.In one exemplary embodiment, the food may be a health functional food such as a female hormone supplement or protein supplement using the isoflavones and proteins of okara.
예시적인 일 구현예에서, 상기 식품은 항비만 효능을 가진 눈개승마와 식이섬유를 함유한 콩비지를 이용한 다이어트식품인 것일 수 있다.In an exemplary embodiment, the food may be a diet food using nungaeseungma, which has anti-obesity effects, and soybean curd, which contains dietary fiber.
또 다른 측면에서, 본 개시물은 상기 눈개승마와 콩비지의 복합 가공물을 제조하는 방법으로, 눈개승마와 콩비지를 혼합하는 단계; 및 상기 혼합된 눈개승마와 콩비지를 함께 열처리하는 단계를 포함하는, 눈개승마와 콩비지의 복합 가공물을 제조하는 방법을 제공한다.In another aspect, the present disclosure is a method of manufacturing a composite product of the snow horse riding horse and soybean curd, comprising the steps of mixing snow horse riding horse and soybean curd; And it provides a method of producing a composite processed product of snow clover and soybean curd, comprising the step of heat-treating the mixed snow pollack and soybean curd together.
예시적인 일 구현예에서, 상기 열처리 단계 이전에 눈개승마와 콩비지를 분쇄하는 단계를 더 포함하는 것일 수 있다. 상기 분쇄는 눈개승마와 콩비지를 각각 분쇄한 후 혼합하거나, 혼합한 후 분쇄하는 것일 수 있다.In one exemplary embodiment, the step of pulverizing the snow and soybean curd may be further included before the heat treatment step. The grinding may be carried out by grinding the nungaeseungma and the soybean curd separately and then mixing them, or mixing them and then grinding them.
예시적인 일 구현예에서, 상기 방법은 눈개승마의 폴리페놀 성분 함량을 증진시키는 것일 수 있다.In one exemplary embodiment, the method may be to increase the content of polyphenol components in snow horse riding horse.
예시적인 일 구현예에서, 상기 방법은 눈개승마의 생체이용성을 증진시키는 것일 수 있다.In one exemplary embodiment, the method may be to enhance the bioavailability of snow horse riding.
눈개승마에 함유된 성분 중 항산화 효능이 뛰어난 폴리페놀 성분은 열에 약해 열가공을 하게 되면 파괴되거나 변형되는 성질을 가지고 있다. 이러한 성질로 인해 카페익산 유도체의 치환기들이 열에 의해 떨어져 나가 항산화 활성이 뛰어난 카페익산과 4-바이닐카테롤 등으로 전환되므로, 열가공 시에 항산화 활성이 더 높아지는 장점을 얻을 수 있다. 그러나, 처리 물질, 온도, 시간 등 가공 조건에 따라 폴리페놀 성분 구성이 달라지고, 가공하지 않은 눈개승마에 비해 폴리페놀 성분이 오히려 감소하게 되는 역효과를 가져올 수도 있다. 본원에 개시된 기술은 눈개승마에 함유된 카페익산 함량을 증진시킬 뿐만 아니라 새로운 항산화 성분 바이닐카테콜을 다량 생성시켜 우수한 항산화, 항염 및/또는 면역증진 효능을 갖는 눈개승마와 콩비지의 복합 가공물 및 이의 제조방법을 제공한다.Among the ingredients contained in snow crab, polyphenol ingredients, which have excellent antioxidant effects, are sensitive to heat and have the property of being destroyed or deformed when heat processed. Due to this property, the substituents of the caffeic acid derivative are removed by heat and converted to caffeic acid and 4-vinyl caterol, which have excellent antioxidant activity, so the advantage of higher antioxidant activity can be obtained during heat processing. However, the composition of polyphenol components varies depending on processing conditions such as processing material, temperature, and time, and may have the adverse effect of reducing polyphenol components compared to unprocessed snow horse riding horse. The technology disclosed herein not only improves the caffeic acid content contained in snow horseradish, but also generates a large amount of vinyl catechol, a new antioxidant ingredient, and produces a composite processed product of snow horse horseradish and soybean curd, which has excellent antioxidant, anti-inflammatory and/or immune-enhancing effects, and the preparation thereof. Provides a method.
이하, 실시예를 통하여 본 개시물을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 개시물을 예시하기 위한 것으로서, 본 개시물의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지 않는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present disclosure will be described in more detail through examples. It will be apparent to those skilled in the art that these examples are solely for illustrating the present disclosure, and that the scope of the present disclosure should not be construed as limited by these examples.
비교예 1. 눈개승마 가공물 제조Comparative Example 1. Manufacture of snow horse riding artifacts
믹서기로 분쇄한 건조 눈개승마 지상부를 3 g씩 무게를 측정하여 오토클레이브 장치로 온도 (100, 110℃)와 시간 (10, 20 ,30 min)에 변화를 주어 열가공하여 가공물을 제조하였다. 대조군으로는 열가공하지 않은 눈개승마 시료를 준비하여 사용하였다.Weighed 3 g of the dried aerial parts of the dried snow gecko pulverized in a blender, and heat-processed them using an autoclave device at varying temperatures (100, 110°C) and times (10, 20, and 30 min) to produce processed products. As a control group, non-heat-processed snow horse riding samples were prepared and used.
이후, 70% (v/v) 에탄올 90 mL로 1시간씩 총 3회 초음파 추출한 다음, 여과지 (Whatman No.1)로 여과하여 감압농축하였다. 각 시료는 70% (v/v) 에탄올을 이용하여 10 mg/mL 농도로 녹여 하기 실험예에서 사용하였다.Afterwards, ultrasonic extraction was performed three times for 1 hour each with 90 mL of 70% (v/v) ethanol, then filtered through filter paper (Whatman No. 1) and concentrated under reduced pressure. Each sample was dissolved in 70% (v/v) ethanol to a concentration of 10 mg/mL and used in the following experimental examples.
실험예Experiment example 1. One. 눈개승마snow dog riding 가공물의 성분 및 Components of processed products and 항산화능Antioxidant ability 분석 analyze
상기 비교예 1에서 제조한 눈개승마 가공물의 성분 및 항산화능을 다음과 같이 분석하였다.The components and antioxidant capacity of the snow horse riding product prepared in Comparative Example 1 were analyzed as follows.
HPLC (High-performance liquid chromatography)는 G1315B Diode Array Detector (DAD) system, G1312A Binary pump, G1329A Auto sampler가 장착되어 있는 Agilent1200 series (Agilent Technologies, USA)를 사용하였다. 데이터 분석은 Chemstation-B.02.01-SRI software를 사용하였고, 항산화능을 분석하기 위해 이 장치에 G1365B Multiple Wavelength Detector (MWD)와 G1379B Degasser, G1310A Iso pump가 추가로 장착된 On-line HPLC-ABTS+ screening system을 사용하여 분석하였다. 분석용 column은 YMC (Kyoto, Japan) ODS-A column (150x4.6mm i.d., 5μm, 12nm)을 사용하였다. UV spectrophotometer는 BioTek (USA)의 Synergy HTX Multi-Mode Reader를 사용하였다.High-performance liquid chromatography (HPLC) was performed using the Agilent1200 series (Agilent Technologies, USA) equipped with a G1315B Diode Array Detector (DAD) system, G1312A Binary pump, and G1329A Auto sampler. Data analysis used Chemstation-B.02.01-SRI software, and to analyze antioxidant capacity, this device was additionally equipped with a G1365B Multiple Wavelength Detector (MWD), G1379B Degasser, and G1310A Iso pump. On-line HPLC-ABTS+ screening It was analyzed using the system. The column for analysis was YMC (Kyoto, Japan) ODS-A column (150x4.6mm i.d., 5μm, 12nm). The UV spectrophotometer used was Synergy HTX Multi-Mode Reader from BioTek (USA).
추출물의 성분을 분석하기 위해 0.1% FA를 첨가한 acetonitrile (용매 A)과 0.1% FA를 첨가한 water (용매 B)를 이동상으로 사용하였다 (표 1 참조). 용매 A와 용매 B의 유속은 0.7 mL/min으로 설정하고 검출 파장은 205 nm, 254 nm, 280 nm, 330 nm로 설정하여 분석하였다.To analyze the components of the extract, acetonitrile (solvent A) with 0.1% FA and water (solvent B) with 0.1% FA were used as mobile phases (see Table 1). The flow rates of solvent A and solvent B were set to 0.7 mL/min, and the detection wavelengths were set to 205 nm, 254 nm, 280 nm, and 330 nm for analysis.
그 결과, 열가공을 하기 전에는 Compound 1-3이 확인되었으며, Compound 2-3의 피크가 가장 크게 나타났다. 그러나, 열가공을 한 후 Compound 2-3의 피크 크기가 감소하였고, Compound 1의 피크 크기가 크게 증가하였으며, 또한 새로운 항산화 물질인 Compound 4가 새로 생성되었다 (도 2 참조).As a result, Compound 1-3 was confirmed before heat processing, and the peak of Compound 2-3 appeared the largest. However, after heat processing, the peak size of Compound 2-3 decreased, the peak size of Compound 1 increased significantly, and a new antioxidant substance, Compound 4, was created (see Figure 2).
HPLC 크로마토그램에서의 피크 면적값을 이용하여 가공 온도와 시간에 따른 눈개승마 가공물에 대한 항산화 성분의 증감 비율을 확인한 결과, 가공하지 않은 눈개승마에 비해 항산화 성분이 100 ℃에서 열가공할 경우 111.62~117.66%로 증가하였고, 110 ℃에서 열가공할 경우 91.82~98.08%로 감소하였다. 특히, 100 ℃에서 10분 동안 열가공한 경우 117.66%로 항산화 성분의 증감 비율이 가장 높은 것으로 나타났다 (도 3 참조).As a result of confirming the increase/decrease rate of antioxidant components in processed snow horse riding products according to processing temperature and time using the peak area value in the HPLC chromatogram, the antioxidant content increased from 111.62 to 111.62 when heat processed at 100 ℃ compared to unprocessed snow horse riding products. It increased to 117.66%, and decreased to 91.82~98.08% when heat processed at 110 ℃. In particular, heat processing at 100°C for 10 minutes showed the highest increase/decrease ratio of antioxidant components at 117.66% (see Figure 3).
또한, DPPH 라디칼 소거능을 다음과 같이 평가하였다. 96 well plate에 농도별 (1, 0.5, 0.25, 0.125 mg/mL)로 제조한 시료 100 μL와 0.5 mM DPPH 시약 100 μL을 혼합하여 암조건에서 30분 동안 반응시킨 후 517 nm에서 흡광도를 측정하였다. DPPH 라디칼 소거능은 아래의 식에 의해 계산하였다.Additionally, the DPPH radical scavenging ability was evaluated as follows. 100 μL of sample prepared at each concentration (1, 0.5, 0.25, 0.125 mg/mL) and 100 μL of 0.5 mM DPPH reagent were mixed in a 96 well plate, reacted for 30 minutes in dark conditions, and absorbance was measured at 517 nm. . DPPH radical scavenging ability was calculated using the formula below.
A : Sample + DPPH, B : Sample에 대한 BLK, C : 용매 + DPPH, D : 용매에 대한 BLKA: Sample + DPPH, B: BLK for Sample, C: Solvent + DPPH, D: BLK for Solvent
그 결과, 100 ℃에서 10분 동안 열가공한 눈개승마 가공물의 DPPH 라디칼 소거능이 가장 높은 것으로 나타났다 (도 4 참조).As a result, it was found that the DPPH radical scavenging ability of the snow horse riding product heat-processed at 100 ° C. for 10 minutes was the highest (see Figure 4).
상기에서와 같이, 100 ℃에서 10분 동안 열가공하였을 때 항산화 성분의 증감 비율과 DPPH 라디칼 소거능이 가장 높은 결과를 바탕으로, 실시예 1에서 눈개승마와 콩비지의 복합 가공물은 100 ℃에서 10분 동안 열처리하는 방법을 적용하여 가공물을 제조하였다.As above, based on the results that the rate of increase/decrease in antioxidant components and the DPPH radical scavenging ability were the highest when heat processed at 100°C for 10 minutes, the composite product of nungaeseungma and soybean curd in Example 1 was heated at 100°C for 10 minutes. The workpiece was manufactured by applying a heat treatment method.
실시예 1. 눈개승마와 콩비지의 복합 가공물 제조Example 1. Manufacture of composite processed products of snow horse riding horse and soybean curd
믹서기로 분쇄한 건조 눈개승마 지상부 3 g을 콩비지 건조 분말과 눈개승마 : 콩비지 = 10 : 1, 10 : 5의 중량 비율로 혼합한 후 오토클레이브 장치를 이용하여 100 ℃에서 10분 동안 열가공하여 복합 가공물을 제조하였다. 대조군으로는 열가공하지 않은 눈개승마 시료를 준비하였다.3 g of the dried aerial part of the dried okara pulverized in a blender was mixed with dried soybean curd powder at a weight ratio of okara: soybean curd = 10:1, 10:5, and then heat-processed at 100°C for 10 minutes using an autoclave device to obtain a composite product. The workpiece was prepared. As a control group, non-heat-processed snow horse riding samples were prepared.
이후, 70% (v/v) 에탄올 90 mL로 1시간씩 총 3회 초음파 추출한 다음, 여과지 (Whatman No.1)로 여과하여 감압농축하였다. 각 시료는 70% (v/v) 에탄올을 이용하여 10 mg/mL 농도로 녹여 하기 실험에서 사용하였다.Afterwards, ultrasonic extraction was performed three times for 1 hour each with 90 mL of 70% (v/v) ethanol, then filtered through filter paper (Whatman No. 1) and concentrated under reduced pressure. Each sample was dissolved in 70% (v/v) ethanol to a concentration of 10 mg/mL and used in the following experiment.
실험예Experiment example 2. 2. 눈개승마와Snow dog horseback riding 콩비지의 복합 가공물의 성분 및 Ingredients of complex processed products of soybean curd and 항산화능Antioxidant ability 분석 analyze
상기 실험예 1과 동일한 방법으로 상기 실시예 1에서 제조한 눈개승마와 콩비지의 복합 가공물의 성분 및 항산화능을 분석하였다.The components and antioxidant capacity of the composite product of nungaeseungma and soybean curd prepared in Example 1 were analyzed in the same manner as in Experimental Example 1.
그 결과, 도 5에 나타난 바와 같이, 열가공하지 않은 눈개승마 시료에서는 Compound 1-3이 확인되었으며, 눈개승마 단독 가공물과 눈개승마와 콩비지의 복합 가공물에서는 Compound 1-4번이 확인되었다. Compound 4는 열가공에 의해 생긴 항산화 물질로, 눈개승마를 단독으로 열가공하였을 때보다 콩비지와 함께 열가공하였을 때 더 많이 생성되었음을 확인하였다. 콩비지 단독 가공물에서는 항산화능을 띠는 성분이 발견되지 않았다.As a result, as shown in Figure 5, Compounds 1-3 were confirmed in the non-heat-processed snow horse riding sample, and Compounds 1-4 were confirmed in the single processed snow horse riding horse and the composite processed product of snow horse riding horse and soybean curd. Compound 4 is an antioxidant produced by heat processing, and it was confirmed that more was produced when Nungae Seungma was heat processed together with soybean curd than when it was heat processed alone. No ingredients with antioxidant properties were found in the processed soybean curd alone.
또한, HPLC-ABTS 크로마토그램에서의 피크 면적값을 이용하여 항산화 성분의 증감 비율을 확인한 결과, 열가공하지 않은 눈개승마 시료와 비교하였을 때 눈개승마 단독 가공물 및 눈개승마-콩비지 복합 가공물 (10:1)의 항산화 성분이 각각 113.32%, 114.13% 증가하는 것으로 나타났다. 특히, 눈개승마-콩비지 복합 가공물 (10:5)의 경우 130.18% 증가하였다 (도 6 참조).In addition, as a result of confirming the increase/decrease ratio of antioxidant components using the peak area value in the HPLC-ABTS chromatogram, compared to the non-heat-processed Nungae Seungma sample, the Nungae Seungma alone processed and the Nungae Seungma - soybean curd composite processed (10:1) ) showed that the antioxidant components increased by 113.32% and 114.13%, respectively. In particular, in the case of nungaeseungma-soybean curd composite product (10:5), it increased by 130.18% (see Figure 6).
(10:1)AD_SCR_AC1
(10:1)
(10:5)AD_SCR_AC1
(10:5)
*증감비율(%) = (AD_SCR_AC1/AD_AC1)×100*Increase/decrease ratio (%) = (AD_SCR_AC1/AD_AC1)×100
표 2에서 확인되는 바와 같이, 눈개승마-콩비지 복합 가공물 (10:1)은 Compound 2-3이 감소하였으며, 눈개승마-콩비지 복합 가공물 (10:5)은 Compound 3만이 감소하였다. 열가공으로 인해 생성된 Compound 4는 눈개승마 단독 가공물에 비해 눈개승마-콩비지 복합 가공물 (10:1)에서는 154.43%, 눈개승마-콩비지 복합 가공물 (10:5)에서는 162.08%로 콩비지의 첨가 비율이 높아질수록 크게 증가하는 것을 확인하였다. 따라서, 본 개시물에 따른 눈개승마와 콩비지의 복합 가공물은 콩비지와의 융합 열가공을 통해 활성성분 생성량이 증진되는 것을 확인하였다.As can be seen in Table 2, Compounds 2-3 of the Nungaeseungma-soybean-okara composite product (10:1) decreased, and only Compound 3 of the Nungaeseungma-soybean-okara composite product (10:5) decreased. Compound 4 created through heat processing has an addition ratio of soybean fat of 154.43% in the snow-gae horse-and-soybean curd composite product (10:1) and 162.08% in the snow-gae horse-soybean curd composite product (10:5) compared to the single-processed product of snow-covered horse. It was confirmed that the higher the level, the greater the increase. Therefore, it was confirmed that the production of active ingredients in the composite product of nungaeseungma and soybean curd according to the present disclosure was increased through fusion heat processing with soybean curd.
실험예Experiment example 3. 세포 독성 평가 3. Cytotoxicity assessment
상기 비교예 1에서 제조한 눈개승마 가공물과 상기 실시예 1에서 제조한 눈개승마와 콩비지의 복합 가공물이 세포생존율에 영향을 미치는지 확인하기 위해 MTT assay를 진행하였다. MTT assay was performed to determine whether the processed product of snow horseradish prepared in Comparative Example 1 and the composite product of dried horseradish and soybean curd prepared in Example 1 affect cell viability.
농도별 (31.25, 62.5, 125, 250 μm/mL)로 제조한 샘플을 마우스 대식세포 Raw 264.7에 24시간 동안 처리한 후, MTT (5 mg/mL) 10 μL씩을 처리하고 37 ℃에서 3시간 동안 배양하였다. 이후, 상층액을 제거하고 형성된 formazan을 녹이기 위해 DMSO 100 μL를 분주하여 상온에 30분 동안 방치한 후 570 nm에서 흡광도를 측정하였다.Samples prepared at different concentrations (31.25, 62.5, 125, 250 μm/mL) were treated with mouse macrophage Raw 264.7 for 24 hours, then treated with 10 μL of MTT (5 mg/mL) and incubated at 37°C for 3 hours. Cultured. Afterwards, the supernatant was removed, 100 μL of DMSO was dispensed to dissolve the formed formazan, the mixture was left at room temperature for 30 minutes, and the absorbance was measured at 570 nm.
그 결과, 가공물은 모든 농도에서 세포 독성을 나타내지 않는 것을 확인하였다 (도 7 참조).As a result, it was confirmed that the processed product did not exhibit cytotoxicity at all concentrations (see Figure 7).
실험예 4. 항염 효능 평가Experimental Example 4. Anti-inflammatory efficacy evaluation
상기 실시예 1에서 제조한 눈개승마와 콩비지의 복합 가공물의 항염 활성을 확인하기 위해 농도별 (31.25, 62.5, 125, 250 μm/mL)로 제조한 샘플과 Lipopolysaccharides (LPS) (1μg/mL)를 마우스 대식세포 Raw 264.7에 24시간 동안 처리한 후 세포배양액과 Griess reagent를 1:1로 섞어 상온에서 15분간 반응시키고 540 nm에서 흡광도를 측정하였다. 양성대조군으로는 NG-methylL-arginine(L-NMMA)를 사용하였다.To confirm the anti-inflammatory activity of the composite product of nungaeseungma and soybean curd prepared in Example 1, samples prepared at different concentrations (31.25, 62.5, 125, 250 μm/mL) and Lipopolysaccharides (LPS) (1 μg/mL) were used. After treating mouse macrophages Raw 264.7 for 24 hours, cell culture medium and Griess reagent were mixed 1:1, reacted at room temperature for 15 minutes, and absorbance was measured at 540 nm. NG-methylL-arginine (L-NMMA) was used as a positive control.
그 결과, 눈개승마와 콩비지의 복합 가공물은 농도 의존적으로 NO 생성 억제 활성을 보였으며, 250 μg/mL 농도에서 가장 활성이 뛰어난 것으로 나타났다. LPS 단독 처리군을 기준으로 하였을 때, 눈개승마-콩비지 복합 가공물 (10:1)은 89.70~8.44%, 눈개승마-콩비지 복합 가공물 (10:5)은 86.83~7.53%까지 억제하여 우수한 항염 활성을 갖는 것을 확인하였다 (도 8 참조).As a result, the composite processed product of nungaeseungma and soybean curd showed NO production inhibitory activity in a concentration-dependent manner, and was found to be most active at a concentration of 250 μg/mL. Based on the LPS-only treatment group, the Nungaeseungma-soybean-okara composite product (10:1) was inhibited by 89.70~8.44%, and the Nungaeseungma-bean-okara composite product (10:5) was inhibited by 86.83~7.53%, showing excellent anti-inflammatory activity. It was confirmed that there was (see FIG. 8).
실험예Experiment example 5. 화합물 분리 및 구조 규명 5. Compound isolation and structure identification
(1) 추출 및 용매 분획(1) Extraction and solvent fractionation
건조된 눈개승마 지상부 60 g을 오토클레이브 장치를 이용하여 110 ℃에서 30분 동안 열가공한 후 70% (v/v) 에탄올을 이용하여 초음파 추출을 1시간씩 3회 반복하여 실시하였다. 그 추출액을 여과지 (Whatman, No.1)로 여과하였고, 회전 증발기 (rotary evaporator)로 40 ℃에서 감압 농축하였다. 이후, 추출물을 증류수에 현탁시켜 n-Hexane (Hex), Ethyl acetate (EA), n-butanol (BuOH) 순으로 분획을 진행하였다. 하기 표 3에 추출물 및 분획물의 수율을 나타내었다.60 g of the dried aerial part of the dried abalone was heat-processed at 110°C for 30 minutes using an autoclave device, and then ultrasonic extraction was performed three times for 1 hour each using 70% (v/v) ethanol. The extract was filtered through filter paper (Whatman, No. 1) and concentrated under reduced pressure at 40°C using a rotary evaporator. Afterwards, the extract was suspended in distilled water and fractionated in the following order: n-Hexane (Hex), Ethyl acetate (EA), and n-butanol (BuOH). Table 3 below shows the yields of extracts and fractions.
활성성분을 분리할 분획물을 선택하기 위해 추출물과 분획물을 HPLC 분석과 DPPH 라디칼 소거능 실험을 진행하였다. HPLC를 통해 각 분획물에서 활성 성분의 존재 여부와 흡광도를 비교하였고, DPPH 라디칼 소거능 측정을 통해 각 분획물의 항산화능을 확인하였다.In order to select a fraction from which to separate the active ingredient, HPLC analysis and DPPH radical scavenging ability tests were performed on the extract and fraction. The presence and absorbance of the active ingredient in each fraction were compared through HPLC, and the antioxidant activity of each fraction was confirmed through measurement of DPPH radical scavenging ability.
그 결과, 눈개승마의 활성성분이 EA층에 많이 함유되어 있는 것을 확인하였고, DPPH 라디칼 소거능 또한 EA층이 가장 높은 것을 확인하였다 (도 10 및 11 참조).As a result, it was confirmed that a lot of the active ingredients of Nungae Seungma were contained in the EA layer, and the DPPH radical scavenging ability was also confirmed to be the highest in the EA layer (see Figures 10 and 11).
(2) 분리 및 정제(2) Separation and purification
EA층을 Preparative-HPLC (Gilson 321, U.S.A)와 Solid phase extraction (SPE)을 이용하여 화합물 4개를 분리하였다.Four compounds were separated from the EA layer using Preparative-HPLC (Gilson 321, U.S.A) and solid phase extraction (SPE).
EA층을 Preparative-HPLC (Gilson 321, U.S.A)로 분리하였으며, Column은 Phenomenex Luna 10 μm C18(2) column (250 × 21.2 mm i.d., 10 μm)을 사용하였고, 이동상으로는 0.05% Formic acid를 첨가한 acetonitrile (Solvent A)과 water (Solvent B)를 사용하였다. 이동상 용매의 유속은 3.0 mL/min, 검출 파장은 254 nm으로 설정하여 Compound 4을 분리하였다.The EA layer was separated by Preparative-HPLC (Gilson 321, U.S.A.), a Phenomenex Luna 10 μm C18(2) column (250 × 21.2 mm i.d., 10 μm) was used as the column, and 0.05% formic acid was added as the mobile phase. Acetonitrile (Solvent A) and water (Solvent B) were used. Compound 4 was separated by setting the mobile phase solvent flow rate to 3.0 mL/min and the detection wavelength to 254 nm.
또한, EA층을 Solid phase extraction (SPE)를 이용하여 100% MeOH로 용리시켜 안정화시킨 후, EA층 1 g을 YMC GEL ODS-A 1 g에 흡착시켜 column에 loading하였다. 이후, 20, 40, 50, 60, 80, 100% MeOH 순으로 용매별로 40 mL씩 용리시켜 AD-EA-F1~F6로 나누었다. 6개의 소분획물의 HPLC 분석 결과, 40% MeOH 소분획물에서 Compound 1-3이 포함되어 있는 것을 확인하였다 (도 12 참조).In addition, the EA layer was stabilized by eluting with 100% MeOH using solid phase extraction (SPE), and then 1 g of the EA layer was adsorbed onto 1 g of YMC GEL ODS-A and loaded onto the column. Afterwards, 40 mL of each solvent was eluted with 20, 40, 50, 60, 80, and 100% MeOH, and divided into AD-EA-F1 to AD-EA-F6. As a result of HPLC analysis of six small fractions, it was confirmed that Compound 1-3 was included in the 40% MeOH small fraction (see Figure 12).
AD-EA-F2 분획을 Preparative-HPLC (Gilson 321, U.S.A)를 이용하여 2차 분리를 하였다. Column은 YMC-Pack ODS-A Column (250 × 10 mm, 5 μm)을 사용하였고, 이동상으로는 0.05% Formic acid를 첨가한 acetonitrile (A)과 Water (B)를 사용하였다. 이동상 용매의 유속은 3.0 mL/min, 검출 파장은 210 nm에서 Compound 1-3을 분리하였다.The AD-EA-F2 fraction was subjected to secondary separation using Preparative-HPLC (Gilson 321, U.S.A.). YMC-Pack ODS-A Column (250 × 10 mm, 5 μm) was used as the column, and acetonitrile (A) and Water (B) with 0.05% formic acid added were used as mobile phases. Compounds 1-3 were separated at a mobile phase solvent flow rate of 3.0 mL/min and a detection wavelength of 210 nm.
(3) 구조 결정(3) Structure determination
분리한 화합물들의 구조를 확인하기 위해 Agilent 1200 series HPLC-MS를 이용하여 분자량과 UV spectrum을 얻었고, VNMRS 500MHz (Varian Inc., Palo Alto, U.S.A) 기기를 이용하여 Compound 1-3는 methanol-d₄ 용매에 녹여 1H-NMR을 측정하였다. Compound 4는 methanol-d₄ 용매에 녹여 1H-NMR, COSY, HSQC, HMBC 스펙트럼을 측정하였다.To confirm the structure of the separated compounds, molecular weight and UV spectrum were obtained using Agilent 1200 series HPLC-MS, and Compound 1-3 was identified as methanol- d ₄ using VNMRS 500MHz (Varian Inc., Palo Alto, USA). It was dissolved in a solvent and 1 H-NMR was measured. Compound 4 was dissolved in methanol- d ₄ solvent and 1 H-NMR, COZY, HSQC, and HMBC spectra were measured.
HPLC-MS와 NMR data를 확인한 결과, Compound 1는 Caffeic acid, 2-3는 Dicaffeoylglucose isomer, 4는 4-vinylcatechol로 확인되었다.As a result of checking HPLC-MS and NMR data, Compound 1 was confirmed to be Caffeic acid, Compound 2-3 was confirmed to be Dicaffeoylglucose isomer, and Compound 4 was confirmed to be 4-vinylcatechol.
No.Compound
No.
m/z [M+H] +
m/z
m/z [MH] -
m/z
a : [M+Na]+a : [M+Na]+
Compound 1은 노란색을 띠는 물질로 UV spectrum의 λmax는 218, 238, 296, 324 nm이며, [M+H]+ m/z = 181.0, [M+Na]+ m/z = 203.0, [M-H]- m/z = 179.0이다, Compound 1은 화학식 1의 카페익산인 것으로 확인되었다.Compound 1 is a yellow material, and the λ max of the UV spectrum is 218, 238, 296, 324 nm, [M+H] + m/z = 181.0, [M+Na] + m/z = 203.0, [ MH] - m/z = 179.0, Compound 1 was confirmed to be caffeic acid of Chemical Formula 1.
[화학식 1][Formula 1]
Compound 2-3은 노란색을 띠는 물질로 UV spectrum의 λmax는 218, 238, 296, 324 nm이며, [M+H]+ m/z = 181.0, [M+Na]+ m/z = 203.0, [M-H]- m/z = 179.0이다. Compound 2-3은 화학식 2, 3의 디카페오일글루코즈 아이소머 (Dicaffeoylglucose isomer)로 확인되었다.Compound 2-3 is a yellow material, and the λ max of the UV spectrum is 218, 238, 296, 324 nm, [M+H] + m/z = 181.0, [M+Na] + m/z = 203.0 , [MH] - m/z = 179.0. Compound 2-3 was confirmed to be a dicaffeoylglucose isomer of formulas 2 and 3.
[화학식 2][Formula 2]
[화학식 3][Formula 3]
Compound 4는 노란색을 띠는 물질로 UV spectrum의 λmax는 214, 260, 298 nm이며, [M+H]+ m/z = 137.2, [M-H]- m/z = 135.1이다. Compound 4는 화학식 4의 4-바이닐카테콜 (4-vinylcatechol)로 확인되었다.Compound 4 is a yellow material, and the λ max of the UV spectrum is 214, 260, 298 nm, [M+H] + m/z = 137.2, [MH] - m/z = 135.1. Compound 4 was confirmed to be 4-vinylcatechol of formula 4.
[화학식 4][Formula 4]
이상, 본 개시물의 특정한 부분을 상세히 기술하였는바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적인 기술은 단지 바람직한 실시 태양일 뿐이며, 이에 의해 본 개시물의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서 본 개시물의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의해 정의된다고 할 것이다.As mentioned above, specific parts of the present disclosure have been described in detail, and it is clear to those skilled in the art that these specific techniques are merely preferred embodiments and do not limit the scope of the present disclosure. something to do. Accordingly, the substantial scope of the present disclosure will be defined by the appended claims and their equivalents.
Claims (11)
상기 복합 가공물은 눈개승마와 콩비지가 1 : 0.4 내지 0.6의 중량비로 혼합되어 함께 열처리된 것이고,
상기 복합 가공물은 바이닐카테콜을 포함하는 것인, 눈개승마와 콩비지의 복합 가공물을 포함하는 식품.
Contains complex processed products of nungaeseungma and soybean curd,
The composite processed product is obtained by heat-treating Nungae Seungma and soybean curd mixed at a weight ratio of 1:0.4 to 0.6,
A food containing a composite processed product of nungaeseungma and soybean curd, wherein the composite processed product contains vinyl catechol.
상기 열처리는 오토클레이브에서 실시하는 것인, 눈개승마와 콩비지의 복합 가공물을 포함하는 식품.
According to clause 1,
A food containing a complex processed product of nungaeseungma and soybean curd, wherein the heat treatment is performed in an autoclave.
상기 열처리는 80 내지 120 ℃에서 실시하는 것인, 눈개승마와 콩비지의 복합 가공물을 포함하는 식품.
According to clause 1,
A food containing a complex processed product of nungaeseungma and soybean curd, wherein the heat treatment is carried out at 80 to 120 ° C.
상기 열처리는 5분 내지 60분 동안 실시하는 것인, 눈개승마와 콩비지의 복합 가공물을 포함하는 식품.
According to clause 1,
A food containing a complex processed product of nungaeseungma and soybean curd, wherein the heat treatment is performed for 5 to 60 minutes.
상기 눈개승마와 콩비지는 1 : 0.5의 중량비로 혼합되어 함께 열처리된 것인, 눈개승마와 콩비지의 복합 가공물을 포함하는 식품.
According to clause 1,
A food containing a composite processed product of snow horse riding and soybean curd, wherein the snow riding horse and soybean curd are mixed at a weight ratio of 1:0.5 and heat treated together.
상기 열처리는 80 내지 110 ℃에서 5분 내지 30분 동안 실시하는 것인, 눈개승마와 콩비지의 복합 가공물을 포함하는 식품.According to clause 1,
A food containing a complex processed product of nungaeseungma and soybean curd, wherein the heat treatment is performed at 80 to 110 ° C. for 5 to 30 minutes.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210056543A KR102666638B1 (en) | 2021-04-30 | 2021-04-30 | Anti-oxidant, anti-inflammatory and/or immunity enhancing compositioin derived from aruncus dioicus-soybean curd residue containing caffeic acid and vinylcatechol |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210056543A KR102666638B1 (en) | 2021-04-30 | 2021-04-30 | Anti-oxidant, anti-inflammatory and/or immunity enhancing compositioin derived from aruncus dioicus-soybean curd residue containing caffeic acid and vinylcatechol |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20220149218A KR20220149218A (en) | 2022-11-08 |
KR102666638B1 true KR102666638B1 (en) | 2024-05-20 |
Family
ID=84041390
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210056543A KR102666638B1 (en) | 2021-04-30 | 2021-04-30 | Anti-oxidant, anti-inflammatory and/or immunity enhancing compositioin derived from aruncus dioicus-soybean curd residue containing caffeic acid and vinylcatechol |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102666638B1 (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101493954B1 (en) | 2013-05-23 | 2015-02-17 | 명지대학교 산학협력단 | Multifunctional soybean byproducts fermented with Aspergillus species, method for preparing the same and use of the same |
-
2021
- 2021-04-30 KR KR1020210056543A patent/KR102666638B1/en active IP Right Grant
Non-Patent Citations (2)
Title |
---|
Korean J. Plant Res. 31(2),117-123쪽(2018.) 1부.* |
Processes, 8(12), 1-11쪽(2020.) 1부.* |
Also Published As
Publication number | Publication date |
---|---|
KR20220149218A (en) | 2022-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Boateng | A critical review of current technologies used to reduce ginkgotoxin, ginkgotoxin-5′-glucoside, ginkgolic acid, allergic glycoprotein, and cyanide in Ginkgo biloba L. seed | |
KR101978336B1 (en) | Method for manufacturing concentrate of Aronia | |
Le et al. | The influence of different drying methods on bioactive components of Eucommia ulmoides Oliver male flower and the comprehensive assessment for industrial application | |
KR20170061327A (en) | Anti-obesity compositions and methods of manufacturing the same as a main component of raspberry leaf and stem extract | |
CN102669352A (en) | Hypolipidemic and hypoglycemic bitter buckwheat tea and preparation method thereof | |
KR102436532B1 (en) | Anti-inflammatory or immunity-boosting composition comprising Protaetia Brevitarsis extract prepared by high pressure-enzymatic hydrolysis system | |
KR20160092631A (en) | The manufacturing method of aronia powder food and the product | |
KR102666638B1 (en) | Anti-oxidant, anti-inflammatory and/or immunity enhancing compositioin derived from aruncus dioicus-soybean curd residue containing caffeic acid and vinylcatechol | |
JP2006306851A (en) | Health food | |
KR20090075481A (en) | Antioxidant composition comprising glycyrrhiza glabra extract | |
JP4352030B2 (en) | healthy food | |
KR102511666B1 (en) | Processing technology for increasing bioactive compounds in potato | |
KR102380812B1 (en) | Processed product of aruncus dioicus having improved bioavailability and mehtod for manufacturing the same | |
JP2008208030A (en) | Inhibitor for lipid accumulation in liver | |
KR101839098B1 (en) | Method of preparing low salted soybean sauce using jeju mandarin | |
KR20170072055A (en) | An antioxidant composition comprising the pachyrhizus erosus root bark extract | |
Boris et al. | Shea press cake, an organic resource of bioactive molecules: biochemical and phytochemical profiles of alcoholic extracts | |
KR102511182B1 (en) | Tofu comprising aruncus dioicus containing polyphenols with enhanced bioavailability and its preparation method | |
KR101879683B1 (en) | Method for preparing soybean sources comprising nipa fruticans wurmb and soybean sources by the method | |
KR102511179B1 (en) | Aruncus dioicus-pressed soy protein complex containing polyphenols with enhanced bioavailability and its preparation method | |
KR101164930B1 (en) | Preparation method of soybean curd comprising sorghum with reinforced tannin and dietary fiber | |
Sheikh et al. | Plum Wastes and By-Products: Chemistry, Processing, and Utilization | |
KR102639344B1 (en) | Complex product of ginseng aerial part and soy protein having enhanced anti-oxidant, skin whitening, skin regeneration and/or anti-inflammatory effect, composition comprising the same and method for prepapring the same | |
JP2006306852A (en) | Anti-obesity agent | |
KR20220141512A (en) | Complex product of platycodon grandiflorus and soy protein having enhanced anti-oxidant and/or anti-inflammatory effect, composition comprising the same and method for prepapring the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |